168 related articles for article (PubMed ID: 27741517)
1. Ral A, via activating the mitotic checkpoint, sensitizes cells lacking a functional Nf1 to apoptosis in the absence of protein kinase C.
Ganapathy S; Fagman JB; Shen L; Yu T; Zhou X; Dai W; Makriyannis A; Chen C
Oncotarget; 2016 Dec; 7(51):84326-84337. PubMed ID: 27741517
[TBL] [Abstract][Full Text] [Related]
2. Induction of mitotic catastrophe by PKC inhibition in Nf1-deficient cells.
Zhou X; Kim SH; Shen L; Lee HJ; Chen C
Cell Cycle; 2014; 13(15):2340-8. PubMed ID: 25483185
[TBL] [Abstract][Full Text] [Related]
3. Ral overactivation in malignant peripheral nerve sheath tumors.
Bodempudi V; Yamoutpoor F; Pan W; Dudek AZ; Esfandyari T; Piedra M; Babovick-Vuksanovic D; Woo RA; Mautner VF; Kluwe L; Clapp DW; De Vries GH; Thomas SL; Kurtz A; Parada LF; Farassati F
Mol Cell Biol; 2009 Jul; 29(14):3964-74. PubMed ID: 19414599
[TBL] [Abstract][Full Text] [Related]
4. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
5. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
[TBL] [Abstract][Full Text] [Related]
7. Characterization of p21Ras-mediated apoptosis induced by protein kinase C inhibition and application to human tumor cell lines.
Liou JS; Chen JS; Faller DV
J Cell Physiol; 2004 Feb; 198(2):277-94. PubMed ID: 14603530
[TBL] [Abstract][Full Text] [Related]
8. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.
Lock R; Ingraham R; Maertens O; Miller AL; Weledji N; Legius E; Konicek BM; Yan SC; Graff JR; Cichowski K
J Clin Invest; 2016 Jun; 126(6):2181-90. PubMed ID: 27159396
[TBL] [Abstract][Full Text] [Related]
9. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
[TBL] [Abstract][Full Text] [Related]
10. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the viability of Nf1 deficient cells by PKC isoforms.
Zhou X; Shen L; Parris T; Huang J; Yi B; Helou K; Chen C
Oncotarget; 2014 Nov; 5(21):10709-17. PubMed ID: 25301738
[TBL] [Abstract][Full Text] [Related]
12. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
14. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis.
Dai C; Santagata S; Tang Z; Shi J; Cao J; Kwon H; Bronson RT; Whitesell L; Lindquist S
J Clin Invest; 2012 Oct; 122(10):3742-54. PubMed ID: 22945628
[TBL] [Abstract][Full Text] [Related]
15. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.
Kraniak JM; Sun D; Mattingly RR; Reiners JJ; Tainsky MA
Mol Cell Biochem; 2010 Nov; 344(1-2):267-76. PubMed ID: 20680410
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells.
Mangoura D; Sun Y; Li C; Singh D; Gutmann DH; Flores A; Ahmed M; Vallianatos G
Oncogene; 2006 Feb; 25(5):735-45. PubMed ID: 16314845
[TBL] [Abstract][Full Text] [Related]
17. PACAP and VIP affect NF1 expression in rat malignant peripheral nerve sheath tumor (MPNST) cells.
Giunta S; Castorina A; Adorno A; Mazzone V; Carnazza ML; D'Agata V
Neuropeptides; 2010 Feb; 44(1):45-51. PubMed ID: 19919880
[TBL] [Abstract][Full Text] [Related]
18. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
19. Nuclear import mechanism of neurofibromin for localization on the spindle and function in chromosome congression.
Koliou X; Fedonidis C; Kalpachidou T; Mangoura D
J Neurochem; 2016 Jan; 136(1):78-91. PubMed ID: 26490262
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2.
Patrakitkomjorn S; Kobayashi D; Morikawa T; Wilson MM; Tsubota N; Irie A; Ozawa T; Aoki M; Arimura N; Kaibuchi K; Saya H; Araki N
J Biol Chem; 2008 Apr; 283(14):9399-413. PubMed ID: 18218617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
